Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The findings highlight an ongoing need for better integration of HIV care with sexual and reproductive health care.
PrEPception, breast feeding and HIV trial participation are front and center in updated federal guidelines.
Globally, a child contracts HIV every 100 seconds. A new, affordable treatment is available, but the COVID-19 pandemic hinders access.
This finding among sub-Saharan Africans is quite concerning since dolutegravir is now the preferred first-line HIV treatment worldwide.
This may reflect loss of the weight-suppressing effect of the older version of the drug.
More studies link dolutegravir and other drugs to weight gain among people with HIV.
The effect is greater for women, and it could have a detrimental effect on pregnancy outcomes at the population level.
Previously, kids weighing 44 to 88 pounds had to take lower doses—which are less available worldwide—and do so more than once a day.
A 2018 report had suggested that HIV-positive women’s use of the drug at conception increased the risk of the rare birth defects.
Two-drug antiretroviral regimens suppress viral load, but three-drug combos may offer additional benefits.
For pregnant women with HIV, dolutegravir-based regimens are apparently safest.
The agency has also lowered the weight threshold for film-coated tablets of the integrase inhibitor.
The study randomized women starting HIV treatment during their third trimester to dolutegravir- or efavirenz-based antiretroviral regimens.
Researchers compared the demographics of participants in randomized controlled trials for antiretrovirals with the global HIV population.
A recent small study examined pairings of antiretrovirals and statins or blood pressure medications.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.